drugset
Drugs / VRC01
last change Dec 2021 re-read 2 minutes ago

VRC01

also known as VRC-HIVMAB060-00-AB

Monoclonal antibody

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · National Institute of Mental Health (NIMH)

Trials 15 · a red edge is where a trial was stopped

today NCT03208231 · Ph 1/2 NCT02797171 · Ph 1 NCT02664415 · Ph 2 NCT02568215 · Ph 2 NCT02591420 · Ph 1 NCT02716675 · Ph 2 NCT02599896 · Ph 1 NCT02411539 · Ph 1 NCT02463227 · Ph 1 NCT02471326 · Ph 1 NCT02256631 · Ph 1 NCT02140255 · Ph 1/2 NCT02165267 · Ph 1 NCT01993706 · Ph 1 NCT01950325 · Ph 1
201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 110 trials
Phase 1 NCT02797171 Mar 2017 → Jun 2019 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02591420 Apr 2016 → Mar 2021 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02599896 Nov 2015 → Jul 2018 — National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02411539 Aug 2015 → Apr 2016 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02463227 Aug 2015 → Mar 2016 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02471326 Jul 2015 → Apr 2017 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02256631 Jun 2015 → Jun 2020 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02165267 Aug 2014 → Feb 2016 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01993706 Nov 2013 → Feb 2015 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01950325 Aug 2013 → Aug 2015 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT03208231 Aug 2018 → Jun 2020 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/2 NCT02140255 Jan 2015 → Jan 2028 expected HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 23 trials
Phase 2 NCT02664415 Aug 2016 → Aug 2017 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT02568215 May 2016 → Mar 2021 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT02716675 Apr 2016 → Dec 2020 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03831945 Comparator Apr 2019 → Dec 2020 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Terminated No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

FieldValueCited text
Known as VRC01 “VRC-HIVMAB060-00-AB (VRC01) is a broadly neutralizing HIV-1 monoclonal antibody (mAb) isolated from the B cells of an HIV-infected patient.” PMID 26332605 ↗ Sep 2015
14

“This is the first clinical trial of the VRC-HIVMAB060-00-AB (VRC01) monoclonal antibody.” NCT01950325 ↗

“VRC-HIVMAB060-00-AB (VRC01)” NCT02471326 ↗

NCT02165267 ↗

NCT02591420 ↗

NCT02664415 ↗

NCT02797171 ↗

NCT02411539 ↗

NCT02599896 ↗

NCT03208231 ↗

NCT02716675 ↗

NCT02568215 ↗

NCT02256631 ↗

NCT02463227 ↗

NCT02140255 ↗
Known as VRC-HIVMAB060-00-AB “experimental human monoclonal antibody (mAb), VRC-HIVMAB060-00-AB (VRC01)” NCT02411539 ↗
4

NCT01993706 ↗

NCT01950325 ↗

NCT03831945 ↗

NCT02471326 ↗
Action Inhibit “In summary, a single infusion of mAb VRC01 significantly decreased plasma viremia and preferentially suppressed neutralization-sensitive virus strains.” PMID 26702094 ↗ Dec 2015
Modality Monoclonal antibody “VRC01 Human Monoclonal Antibody” NCT01950325 ↗
Route Intravenous “Administered intravenously or subcutaneously to HIV-Infected Adults” NCT01950325 ↗
Route Subcutaneous “Administered intravenously or subcutaneously to HIV-Infected Adults” NCT01950325 ↗